


PHARMACEUTICAL 2019



UNITED THERAPEUTICS Corp Rank 11 of 371





RealRate

PHARMACEUTICAL 2019



UNITED THERAPEUTICS Corp Rank 11 of 371

The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 421% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 276%, being 607% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	1,768,000
Cost of Goods Sold	198,700
Intangible Assets	0
Liabilities, Current	276,600
Liabilities, Non-Current	66,600
Other Assets	933,300
Other Compr. Net Income	11,700
Other Expenses	169,700
Other Liabilities	250,000
Other Net Income	-46,500
Property and Equipment	699,700
Research and Development	357,900
Revenues	1,627,800
Selling, General and Administrative Expense	265,800

Output Variable	Value in 1000 USD
Assets	3,401,000
Liabilities	593,200
Expenses	992,100
Stockholders Equity	2,807,800
Net Income	589,200
Comprehensive Net Income	595,050
Economic Capital Ratio	276%